Linda Stocum, Associate Editor

Omeza announced yesterday that the FDA has given 510(k) clearance for the Omeza Collagen Matrix for chronic wound care.

A study published in the Journal of Dermatological Treatment shows guselkumab may be more effective in heavier patients with moderate to severe plaque psoriasis vs secukinumab.

Pfizer’s JADE DARE phase 3 trial met its coprimary and key secondary efficacy endpoints.

Crown Laboratories and L Catterton announce they will acquire StriVectin to create Crown Premium Skincare.

Regeneron Pharmaceuticals, Inc. and Sanofi announced safety and efficacy results from the LIBERTY AD trial investigating dupilumab in pediatric patients ages 6 months to 5 years with atopic dermatitis.

ICYMI, some of this week’s featured content includes the ACP encouraging all vaccinations, video interviews diet and supplement in psoriasis treatment, articles on safety, efficacy study results for abrocitinib, SCALE conference coverage and more.

Upadacitinib has been approved by the European Commision and becomes the first Janus kinase (JAK) inhibitor approved in the European Union for the treatment of moderate to severe atopic dermatitis in adult and pediatric patients.

In this video interview, Monica Bonakdar, MD, shares her thoughts on combination therapies, how COVID-19 affected her practice, and more.

UCB announced the European Commission have granted marketing authorization for bimekizumab for the treatment of moderate to severe plaque psoriasis.

Jennifer Powers, MD, associate professor of dermatology at the University of Iowa, talks her recent research investigating how diet and supplements affect patients with mild psoriasis.

A study published in the Dermatol Ther (Heidelb) journal performed an investigational overview on estrogens and their impact on health while explaining how this leads to cosmeceuticals for female patients with estrogen-deficient skin.

A pilot study from the Journal of Cosmetic Dermatology investigated the efficacy and tolerability of a comprehensive antioxidant treatment for male patients seeking skin improvement.

A recent study investigated the difference between skin microbiota in patients with acne and controls without acne.

Jason Emer, MD, in this video interview, discusses plasma pen cosmetic treatments, the influx of patient interest, dangers of non-FDA cleared pens, and how to work with SOC patients.

A study published in JAMA Dermatology investigated the strain acne puts on the lives of adult women.

Eli Lilly announced that lebrikizumab has met all primary and key secondary endpoints at week 16 in their 2 phase 3 trials.

A study published in the Journal of the American Academy of Dermatology examined the potential relationship between air pollution and the incidence of atopic dermatitis.

GlobalData has published a report that predicts the atopic dermatitis pipeline will see great transformation and growth in the next 10 years.

A phase 2 clinical trial on remetinostat for the treatment of BCC in adult patients has been published in the Clinical Cancer Research journal and shows promising results.

Do COVID-19 antigens cause hypersensitivity to dermal fillers?

In honor of National Hair Loss Awareness Month, Nutrafol pledges to donate a portion of its’ total revenue in the month of August to the National Alopecia Areata Foundation.

The FDA has granted priority review to Merck’s application for pembrolizumab, a treatment for melanoma.

UCB announced that more than 90% of patients treated with bimekizumab have maintained IGA 1/0 results in their long-term BE BRIGHT trial.

Researchers from UT Southwestern Medical Center have investigated a new way to use AI to determine the metastatic potential of melanoma.

Shino Bay Aguilera, DO, reflects on his keynote address highlighting diversity and wellness in aesthetic medicine at Aesthetics Biomedical’s “Perspectives: The Evolution of Aesthetics” symposium.

In this first part of our coverage of “The Skin of Color Update Pre-Conference Virtual Symposium” held August 3, we review challenging cases of melasma, vitiligo, and post-inflammatory hyperpigmentation in skin of color patients.

The results from the Heads Up study were published in JAMA Dermatology, which demonstrated upadacitinib was superior to dupilumab in treating atopic dermatitis.

In this video interview, Jerry Bagel, MD, MS, discusses improvement in quality of life for pediatric psoriasis patients and current and emerging treatments.

MediWound Ltd, announced the results for its CIDS trial studying NexoBrid as a treatment for children with severe thermal burns.

Take a look behind the scenes at the Aesthetics Biomedical's "Perspectives: The Evolution of Aesthetics" symposium held July 24th in Orlando, Florida.